MX2017009110A - Terapia de combinacion para hipertension pulmonar. - Google Patents
Terapia de combinacion para hipertension pulmonar.Info
- Publication number
- MX2017009110A MX2017009110A MX2017009110A MX2017009110A MX2017009110A MX 2017009110 A MX2017009110 A MX 2017009110A MX 2017009110 A MX2017009110 A MX 2017009110A MX 2017009110 A MX2017009110 A MX 2017009110A MX 2017009110 A MX2017009110 A MX 2017009110A
- Authority
- MX
- Mexico
- Prior art keywords
- pulmonary hypertension
- combination therapy
- bmpr2
- treatment
- combination
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 3
- 208000002815 pulmonary hypertension Diseases 0.000 title abstract 3
- 102100025422 Bone morphogenetic protein receptor type-2 Human genes 0.000 abstract 3
- 101000934635 Homo sapiens Bone morphogenetic protein receptor type-2 Proteins 0.000 abstract 3
- 239000012190 activator Substances 0.000 abstract 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229960001967 tacrolimus Drugs 0.000 abstract 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562103020P | 2015-01-13 | 2015-01-13 | |
| PCT/US2016/012694 WO2016114993A1 (en) | 2015-01-13 | 2016-01-08 | Combination therapy for pulmonary hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017009110A true MX2017009110A (es) | 2017-11-09 |
Family
ID=56406244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017009110A MX2017009110A (es) | 2015-01-13 | 2016-01-08 | Terapia de combinacion para hipertension pulmonar. |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20180325875A1 (enExample) |
| EP (1) | EP3244968B1 (enExample) |
| JP (1) | JP6890540B2 (enExample) |
| KR (1) | KR102569428B1 (enExample) |
| CN (1) | CN107427698A (enExample) |
| AU (1) | AU2016207046B2 (enExample) |
| BR (1) | BR112017014914B1 (enExample) |
| CA (1) | CA2973114C (enExample) |
| IL (1) | IL253325A0 (enExample) |
| MX (1) | MX2017009110A (enExample) |
| NZ (1) | NZ733451A (enExample) |
| WO (1) | WO2016114993A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160317542A1 (en) | 2013-12-09 | 2016-11-03 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
| JP2019533713A (ja) * | 2016-11-10 | 2019-11-21 | アレーナ ファーマシューティカルズ，インク． | ラリンパグと他の薬剤とを組み合わせた肺動脈高血圧症を処置する方法 |
| CN110381951A (zh) * | 2016-12-14 | 2019-10-25 | 瑞必治公司 | 用于治疗肺性高血压和其他肺病症的方法及组合物 |
| CN112569357B (zh) * | 2019-09-30 | 2023-03-28 | 深圳奥萨制药有限公司 | 双重内皮素受体拮抗剂与利尿剂的组合物 |
| BR112022010311A2 (pt) | 2019-11-29 | 2022-08-16 | Actelion Pharmaceuticals Ltd | Métodos de tratamento de hipertensão arterial pulmonar |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110171193A1 (en) * | 2008-06-12 | 2011-07-14 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating pulmonary hypertension |
| PT3821891T (pt) * | 2011-05-02 | 2023-08-31 | Univ Leland Stanford Junior | Utilização de fk506 para o tratamento da hipertensão arterial pulmonar |
| CN103814131A (zh) | 2011-05-09 | 2014-05-21 | 格拉斯哥大学理事会 | 在肺动脉高血压的治疗中调控microrna的方法 |
| WO2013142369A1 (en) * | 2012-03-23 | 2013-09-26 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of pulmonary hypertension with leukotriene inhibitors |
-
2016
- 2016-01-08 BR BR112017014914-1A patent/BR112017014914B1/pt active IP Right Grant
- 2016-01-08 KR KR1020177022273A patent/KR102569428B1/ko active Active
- 2016-01-08 WO PCT/US2016/012694 patent/WO2016114993A1/en not_active Ceased
- 2016-01-08 NZ NZ733451A patent/NZ733451A/en unknown
- 2016-01-08 CN CN201680015289.1A patent/CN107427698A/zh active Pending
- 2016-01-08 JP JP2017536934A patent/JP6890540B2/ja active Active
- 2016-01-08 MX MX2017009110A patent/MX2017009110A/es unknown
- 2016-01-08 CA CA2973114A patent/CA2973114C/en active Active
- 2016-01-08 US US15/543,510 patent/US20180325875A1/en not_active Abandoned
- 2016-01-08 EP EP16737651.6A patent/EP3244968B1/en active Active
- 2016-01-08 AU AU2016207046A patent/AU2016207046B2/en active Active
-
2017
- 2017-07-05 IL IL253325A patent/IL253325A0/en unknown
-
2019
- 2019-04-11 US US16/381,128 patent/US20200069658A1/en not_active Abandoned
-
2021
- 2021-05-11 US US17/317,274 patent/US20210267951A1/en not_active Abandoned
-
2024
- 2024-03-28 US US18/620,058 patent/US20240238259A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017128481A3 (enExample) | 2019-06-25 |
| EP3244968B1 (en) | 2023-08-30 |
| KR20170103918A (ko) | 2017-09-13 |
| CN107427698A (zh) | 2017-12-01 |
| EP3244968A1 (en) | 2017-11-22 |
| BR112017014914B1 (pt) | 2023-11-14 |
| EP3244968A4 (en) | 2018-09-12 |
| CA2973114C (en) | 2023-04-04 |
| KR102569428B1 (ko) | 2023-08-21 |
| AU2016207046B2 (en) | 2021-04-01 |
| CA2973114A1 (en) | 2016-07-21 |
| US20200069658A1 (en) | 2020-03-05 |
| NZ733451A (en) | 2023-02-24 |
| US20210267951A1 (en) | 2021-09-02 |
| US20240238259A1 (en) | 2024-07-18 |
| WO2016114993A1 (en) | 2016-07-21 |
| BR112017014914A2 (pt) | 2018-03-13 |
| JP6890540B2 (ja) | 2021-06-18 |
| US20180325875A1 (en) | 2018-11-15 |
| JP2018502126A (ja) | 2018-01-25 |
| RU2017128481A (ru) | 2019-02-14 |
| AU2016207046A1 (en) | 2017-07-27 |
| IL253325A0 (en) | 2017-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201807399B (en) | Egfr inhibitor compounds | |
| PH12017502107A1 (en) | Triazole agonists of the apj receptor | |
| CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
| MA39986A (fr) | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer | |
| TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
| PH12017500881B1 (en) | Aurora a kinase inhibitor | |
| EP4327809A3 (en) | Tyk2 inhibitors and uses thereof | |
| SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
| EP4193993A3 (en) | Combinations of cannabinoids and n-acylethanolamines | |
| WO2015153514A8 (en) | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists | |
| MX2018006632A (es) | Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4). | |
| PH12016500270A1 (en) | Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases | |
| MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
| CA2986759C (en) | AUTOTAXIN INHIBITORS AND THEIR USES | |
| HK1254954A1 (zh) | Lpt-723和免疫检查点抑制剂组合物及其治疗方法 | |
| PH12016501751A1 (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
| WO2015181624A3 (en) | Nucleoside derivatives for the treatment of cancer | |
| PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| NZ733451A (en) | Combination therapy for pulmonary hypertension | |
| PH12017501022B1 (en) | Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| MX2016015568A (es) | Derivados de nucleosidos para el tratamiento del cancer. | |
| MX2019009200A (es) | Composiciones y métodos para inhibir el reticulón 4. | |
| HK1255041A1 (zh) | Fxia抑制剂的逆转剂 | |
| MX2017014301A (es) | Composiciones y metodos para el tratamiento o prevencion de hipertension pulmonar. |